Year-End Submissions Total 17, Including Four From Aventis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Aventis was the most prominent participant in the year-end NDA filing rush, submitting four applications: two new molecular entities, a vaccine and a new formulation.